Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant palbociclib plus endocrine therapy versus endocrine therapy alone for resected isolated locoregional recurrence of HR-positive/HER2-negative breast cancer
2018-003553-19Phase 3Active
- Sponsor
- International Breast Cancer Study Group
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of palbociclib in breast cancer (2 arms), sponsored by International Breast Cancer Study Group. Primary endpoint: Invasive disease-free survival. Started Jun 2019; status: active.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-003553-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003553-19.